XML 57 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814
Net Income (Loss) Per Share (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Numerator        
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. $ 5,594,468 $ (7,177,575) $ (11,235,561) $ (28,710,309)
Reflect adjustment for decrease in fair value of warrant liability (616,477) (271,022) (928,978) (1,996,544)
Numerator for use in diluted income (loss) per share $ 4,977,991 $ (7,448,597) $ (12,164,539) $ (30,706,853)
Denominator        
Weighted average number of common shares outstanding (shares) 72,029,644 60,392,911 66,846,481 58,625,740
Effect of dilutive potential common shares from warrants (shares) 1,931,593 209,920 172,480 310,674
Denominator for use in diluted loss per share (shares) 73,961,237 60,602,831 67,018,961 58,936,414
Net loss per share, diluted ($ per share) $ 0.07 $ (0.12) $ (0.18) $ (0.52)
Antidilutive securities excluded from computation of earnings per share, amount (shares) 2,820,641 5,820,385 6,694,571 5,820,385
Options to purchase commons stock [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares) 2,812,185 4,833,877 5,875,211 4,833,877
Warrants to purchase common stock [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares) 0 978,052 580,904 978,052
Restricted stock units [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares)     230,000 0
Convertible preferred stock [Member]        
Denominator        
Antidilutive securities excluded from computation of earnings per share, amount (shares) 8,456 8,456 8,456 8,456